Search

Your search keyword '"Domselaar, M."' showing total 4 results
Start Over Author "Domselaar, M." Journal american journal of gastroenterology
4 results on '"Domselaar, M."'

1. Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study

Author

Chaparro, M, primary, Verreth, A, additional, Lobaton, T, additional, Gravito-Soares, E, additional, Julsgaard, M, additional, Savarino, E, additional, Magro, F, additional, Biron, Avni I, additional, Lopez-Serrano, P, additional, Casanova, M J, additional, Gompertz, M, additional, Vitor, S, additional, Arroyo, M, additional, Pugliese, D, additional, Zabana, Y, additional, Vicente, R, additional, Aguas, M, additional, Shitrit, Bar-Gil A, additional, Gutierrez, A, additional, Doherty, G A, additional, Fernandez-Salazar, L, additional, Cadilla, Martínez J, additional, Huguet, J M, additional, O'Toole, A, additional, Stasi, E, additional, Marcos, Manceñido N, additional, Villoria, A, additional, Karmiris, K, additional, Rahier, J F, additional, Rodriguez, C, additional, Palomares, Diz-Lois M, additional, Fiorino, G, additional, Benitez, J M, additional, Principi, M, additional, Naftali, T, additional, Taxonera, C, additional, Mantzaris, G, additional, Sebkova, L, additional, Iade, B, additional, Lissner, D, additional, Bradley, Ferrer I, additional, Roman, Lopez-San A, additional, Marin-Jimenez, I, additional, Merino, O, additional, Sierra, M, additional, Van Domselaar, M, additional, Caprioli, F, additional, Guerra, I, additional, Peixe, P, additional, Piqueras, M, additional, Rodriguez-Lago, I, additional, Ber, Y, additional, van Hoeve, K, additional, Torres, P, additional, Gravito-Soares, M, additional, Rudbeck-Resdal, D, additional, Bartolo, O, additional, Peixoto, A, additional, Martin, G, additional, Armuzzi, A, additional, Garre, A, additional, Donday, M G, additional, de Carpi, Martín F J, additional, and Gisbert, J P, additional

Published
2018
Full Text
View/download PDF

2. Extracolonic Cancer in Inflammatory Bowel Disease: Data from the GETECCU Eneida Registry

Author

Chaparro, María, primary, Ramas, M, additional, Benítez, J M, additional, López-García, A, additional, Juan, A, additional, Guardiola, J, additional, Mínguez, M, additional, Calvet, X, additional, Márquez, L, additional, Salazar, L I Fernández, additional, Bujanda, L, additional, García, C, additional, Zabana, Y, additional, Lorente, R, additional, Barrio, J, additional, Hinojosa, E, additional, Iborra, M, additional, Cajal, Domínguez M, additional, Van Domselaar, M, additional, García-Sepulcre, M F, additional, Gomollón, F, additional, Piqueras, M, additional, Alcaín, G, additional, García-Sánchez, V, additional, Panés, J, additional, Domènech, E, additional, García-Esquinas, E, additional, Rodríguez-Artalejo, F, additional, and Gisbert, J P, additional

Published
2017
Full Text
View/download PDF

3. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study

Author

Casanova, M J, primary, Chaparro, M, additional, García-Sánchez, V, additional, Nantes, O, additional, Leo, E, additional, Rojas-Feria, M, additional, Jauregui-Amezaga, A, additional, García-López, S, additional, Huguet, J M, additional, Arguelles-Arias, F, additional, Aicart, M, additional, Marín-Jiménez, I, additional, Gómez-García, M, additional, Muñoz, F, additional, Esteve, M, additional, Bujanda, L, additional, Cortés, X, additional, Tosca, J, additional, Pineda, J R, additional, Mañosa, M, additional, Llaó, J, additional, Guardiola, J, additional, Pérez-Martínez, I, additional, Muñoz, C, additional, González-Lama, Y, additional, Hinojosa, J, additional, Vázquez, J M, additional, Martinez-Montiel, M P, additional, Rodríguez, G E, additional, Pajares, R, additional, García-Sepulcre, M F, additional, Hernández-Martínez, A, additional, Pérez-Calle, J L, additional, Beltrán, B, additional, Busquets, D, additional, Ramos, L, additional, Bermejo, F, additional, Barrio, J, additional, Barreiro-de Acosta, M, additional, Roncedo, O, additional, Calvet, X, additional, Hervías, D, additional, Gomollón, F, additional, Domínguez-Antonaya, M, additional, Alcaín, G, additional, Sicilia, B, additional, Dueñas, C, additional, Gutiérrez, A, additional, Lorente-Poyatos, R, additional, Domínguez, M, additional, Khorrami, S, additional, Taxonera, C, additional, Rodríguez-Pérez, A, additional, Ponferrada, A, additional, Van Domselaar, M, additional, Arias-Rivera, M L, additional, Merino, O, additional, Castro, E, additional, Marrero, J M, additional, Martín-Arranz, M, additional, Botella, B, additional, Fernández-Salazar, L, additional, Monfort, D, additional, Opio, V, additional, García-Herola, A, additional, Menacho, M, additional, la Piscina, Ramírez-de P, additional, Ceballos, D, additional, Almela, P, additional, Navarro-Llavat, M, additional, Robles-Alonso, V, additional, Vega-López, A B, additional, Moraleja, I, additional, Novella, M T, additional, Castaño-Milla, C, additional, Sánchez-Torres, A, additional, Benítez, J M, additional, Rodríguez, C, additional, Castro, L, additional, Garrido, E, additional, Domènech, E, additional, García-Planella, E, additional, and Gisbert, J P, additional

Published
2017
Full Text
View/download PDF

4. Outcomes of pregnancies fathered by inflammatory bowel disease patients exposed to thiopurines.

Author

Teruel C, López-San Román A, Bermejo F, Taxonera C, Pérez-Calle JL, Gisbert JP, Martín-Arranz M, Ponferrada A, Van Domselaar M, Algaba A, Estellés J, López-Serrano P, Linares PM, and Muriel A

Subjects
Azathioprine therapeutic use, Female, Humans, Immunosuppressive Agents adverse effects, Immunosuppressive Agents therapeutic use, Male, Mercaptopurine therapeutic use, Odds Ratio, Pregnancy, Pregnancy Outcome, Spain, Treatment Outcome, Azathioprine adverse effects, Fathers, Inflammatory Bowel Diseases drug therapy, Mercaptopurine adverse effects, Pregnancy Complications chemically induced
Abstract

Objectives: Immunomodulators are used as maintenance treatment of inflammatory bowel disease (IBD). Data regarding their possible effects in the course of pregnancy when the father is exposed at the time of conception are limited., Methods: To evaluate the outcomes of pregnancies of which the fathers were exposed to thiopurines at the time of conception. A series of male patients followed in seven IBD clinics in Madrid, Spain, was studied. Any exposure to thiopurines during the 3 months preceding conception was considered significant. Controls were pregnancies fathered by patients who either had never been treated with thiopurines or had interrupted them >3 months before conception. Statistical comparisons and multivariate analysis were carried out with the generalized estimating equations model., Results: There were 46 conceptions in the exposed group (mercaptopurine 9, azathioprine 37) and 84 in the control group. In the exposed group, there were more Crohn's patients (82.6% vs. 53.6%), the duration of the disease was longer (median: 8 vs. 5 years), fathers were slightly older (mean: 34.2 vs. 32.7 years), and there were fewer patients on mesalamine (15.2% vs. 47.6%). Otherwise, baseline characteristics were similar in both groups. There were no significant differences regarding unsuccessful pregnancies-namely, spontaneous abortions, ectopic pregnancies, anembryonic pregnancies, or fetal deaths (10.9% exposed group vs. 13.1% control group; odds ratio (OR): 0.79, confidence interval (CI): 0.22-2.85), preterm births (4.3% vs. 2.4%; OR: 1.3, CI: 0.22-7.61), low birth weight (6.5% vs. 6%; OR: 1.06, CI: 0.25-4.54), or congenital malformations (2.2% vs. 2.4%; OR: 0.82, CI: 0.08-9). No infant neoplasms were detected. The proportion of conceptions that needed >1 year to be achieved was higher in the exposed group, but this was not statistically significant (15.2% vs. 8.3%; OR: 1.92, CI: 0.54-6.88). Multivariate analysis was carried out for unsuccessful pregnancies and fertility impairment, and it showed that, although mesalamine exposure confounded the effect of the exposure to thiopurines on these outcomes, this effect was still nonsignificant (respectively, OR: 0.49, CI: 0.17-1.44; OR: 2.82, CI: 0.7-11.38)., Conclusions: Our data do not support the practice of routinely recommending to male patients that they interrupt thiopurines when wanting to conceive.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results